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Abstract
Purpose To demonstrate the efficacy and safety of ranibizumab 0.5 mg pro re nata (PRN) versus laser photocoagulation for the
treatment of Chinese patients with visual impairment due to diabetic macular edema (DME).
Methods REFINE was a phase III, 12-month, double-masked, multicenter, laser-controlled study in patients (aged ≥ 18 years)
with DME. Patients were randomized 4:1 to receive either ranibizumab 0.5 mg or laser dosing regimen. Efficacy was evaluated as
mean average change in best-corrected visual acuity (BCVA) from Months 1 to 12 versus baseline (primary endpoint), anatom-
ical outcomes, treatment exposure, and safety were also assessed.
Results Ranibizumab was statistically superior (p < 0.001) to laser treatment, with a mean average BCVA gain of 6.8 letters
(ranibizumab) over 12 months versus 1.1 letters (laser). At Month 12, mean BCVA gain was 7.8 letters (ranibizumab) and 2.5
letters (laser) from baseline. Patients in the ranibizumab arm received a mean number of 7.9 intravitreal injections, whereas those
in the laser arm received a mean of 2.1 treatments. There were no new safety signals.
Conclusion Ranibizumab 0.5 mg PRN demonstrated a statistically significant and clinically meaningful treatment effect versus
laser and was well tolerated in Chinese patients with visual impairment due to DME over 12 months.
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Introduction
Diabetic retinopathy (DR) is a leading cause of visual impair-
ment and blindness in the global population aged 20–74 years
[1, 2] and is an increasing concern with the rising prevalence
of diabetes [3]. Diabetic macular edema (DME) is a common
manifestation of DR and a cause of serious central visual loss
and impairment in diabetic patients if left untreated [4].
Timely intervention in patients with diabetes can help to pre-
vent vision deterioration and lower the risk of blindness due to
DME.
This is particularly relevant for China, as at least 50% of its
population (aged ≥ 18 years) have been shown to have pre-
diabetes based on a 2010 nationwide survey [5]. In another
nationally representative cross-sectional survey conducted in
2013 in mainland China, it reported 35.7% of population aged
≥ 18 years with pre-diabetes [6]. For patients with a confirmed
diagnosis of diabetes, two epidemiological studies in 2642 to
7577 patients conducted in China in 2010 and 2011 have
reported a high prevalence of DR (9.4% to 43.1% of patients,
Electronic supplementary material The online version of this article
(https://doi.org/10.1007/s00417-018-04213-x) contains supplementary
material, which is available to authorized users.
* Xiaoxin Li
drlixiaoxin@163.com
1 Department of Ophthalmology, Peking University People’s Hospital,
No. 11 Xi Zhi Men South Ave., Xicheng District, Beijing 100044,
China
2 Department of Ophthalmology, Beijing Hospital, National Center of
Gerontology, Beijing, China
3 Tianjin Medical University Eye Hospital, Tianjin, China
4 Tianjin Eye Hospital, Tianjin, China
5 Novartis Pharma AG, Basel, Switzerland
6 China Novartis Institutes for BioMedical Research Co. Ltd.,
Shanghai, China
7 Department of Ophthalmology, Inselspital, Bern University Hospital,
University of Bern, Bern, Switzerland
Graefe's Archive for Clinical and Experimental Ophthalmology
https://doi.org/10.1007/s00417-018-04213-x
respectively) and its associated risks including longer duration
of diabetes, higher plasma concentration of glycated hemoglo-
bin (HbA1c), higher postprandial blood glucose concentra-
tions, and higher systolic blood pressure [7–9]. In a cross-
sectional study of 17,985 patients in Beijing, the prevalence
of DR was reported to be 8.1% [10].
Macular edema is a vision threatening complication of
DR. In the Beijing Eye Study, which included 4439 patients
with diabetes mellitus aged > 40 years, the overall preva-
lence of macular edema was 5.2% [11]. An epidemiologic
study in the Shanghai city region in China identified 829
patients > 15 years old with diabetes, of whom 36 (4.34%)
had macular edema [12].
Laser photocoagulation is currently considered the stan-
dard of care for visual impairment due to DME in China,
which stabilizes rather than improves vision in these patients
[13]. Furthermore, 13% of laser-treated eyes remain unrespon-
sive to treatment and are at risk of progressive vision loss [13].
Therefore, there is a need for a treatment that not only halts
progressive vision loss but also has a quick effect on improv-
ing visual acuity (VA) in Chinese patients with DME.
Vascular endothelial growth factor (VEGF) levels are ele-
vated in the vitreous of eyes with DR; therefore, anti-VEGFs
are an alternative treatment for patients with DME [14, 15].
Ranibizumab 0.5 mgwas the first anti-VEGF approved for the
treatment of visual impairment due to DME in Europe (2011)
based on the data from the RESOLVE [16] and RESTORE
[17] studies. These studies enrolled predominantly Caucasian
patients and demonstrated significant and continuous im-
provement in VA over 12 months compared with sham or
laser in patients with visual impairment due to DME.
Currently in China, ranibizumab 0.5 mg is only approved
for the treatment of neovascular age-related macular degener-
ation [18].
Here, we present the 12-month findings of the REFINE
study that was conducted to provide additional data on the
efficacy and safety of ranibizumab 0.5 mg compared with
laser photocoagulation in Chinese patients with visual impair-
ment due to DME.
Methods
Study design
REFINE was a phase III, 12-month, multicenter (28 sites)
laser-controlled study conducted in mainland Chinese patients
with visual impairment due to DME from November 2014 to
January 2017. To minimize potential bias, the study had a
parallel, randomized, double-masked design. Written in-
formed consent was obtained from each patient before
randomization.
The study was conducted according to the ethical prin-
ciples of the Declaration of Helsinki, and the study proto-
col was reviewed by the Ethics Committee for each center.
The study is registered at clinicaltrials.gov with identifier
NCT02259088.
Patient population
The study population consisted of Chinese male and female
patients aged ≥ 18 years with either type I or type II diabetes
mellitus (according to the American Diabetes Association or
World Health Organization guidelines [19]) and HbA1c ≤
10.0% at screening. Patients were included in the study with
visual impairment due to focal or diffuse DME in at least one
eye with a best-corrected VA (BCVA) score between 78 and
39 letters (inclusively, approximately 20/32 to 20/160 Snellen
equivalent) as measured by Early Treatment Diabetic
Retinopathy Study (ETDRS)-like charts at four meters. If both
eyes were eligible, the eye with the worse VA at screening or
baseline visits was selected as the study eye, unless the eye
with the better VA was deemed to be more appropriate for
study by the investigator based on medical reasons.
Patients with any type of systemic disease including those
who had received treatment for it or any medical condition
(controlled or uncontrolled) that could be expected to prog-
ress, recur, or change to an extent that it might influence the
assessment of the clinical status of the patient to a significant
degree or put the patient at special risk; uncontrolled systolic
blood pressure of > 160 mmHg or diastolic blood pressure of
> 100 mmHg; and laser (panretinal, focal, grid) photocoagu-
lation within 3 months prior to baseline visit (study eye) were
excluded from the study. Detailed inclusion and exclusion
criteria are provided in the A1.
Randomization and treatment
Patients were randomized 4:1 into two treatment arms to re-
ceive either ranibizumab 0.5 mg (pro re nata [PRN] dosing
regimen) or laser photocoagulation (as needed according to
ETDRS guidelines) (Fig. 1). A randomization list was pro-
duced by the interactive response technology (IRT) provider
by using a validated system that automated the random assign-
ment of patient numbers to randomization numbers.
In the REFINE study, the treatment regimen was based on
the EU Summary of Product Characteristics 2011 (three
monthly injections followed by PRN as per VA stabilization
criterion) [20].
Ranibizumab arm All patients received three initial monthly
ranibizumab 0.5-mg injections (on Day 1, Month 1, and
Month 2), and sham laser photocoagulation on Day 1, follow-
ed by monthly ranibizumab based on a PRN dosing regimen
until stable VAwas achieved.
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Stable VAwas defined over three consecutive monthly as-
sessments post-baseline, with study treatment given at each
visit. If stable VAwas achieved (at Month 3 or any later time
point), treatment was stopped. Treatment with ranibizumab
was resumed upon any loss of VA due to disease activity
and continued until stable VA was reached again for three
consecutive monthly assessments. Thus, after reinitiation of
ranibizumab injections, a minimum of two successive month-
ly treatments were required.
Laser arm Patients received active laser photocoagulation on
Day 1 (with option to split into two sessions with maximum of
4-week interval in between), and sham ranibizumab injection
on Day 1, Month 1, and Month 2.
If stable VA was achieved, sham injections were
discontinued. Monthly treatment with sham injections was
resumed upon any loss of VA due to disease activity and
continued until stable VAwas reached again for three consec-
utive monthly assessments.
After Day 1, active laser photocoagulation was given as
needed as per the ETDRS guidelines at intervals of no less
than 3 months. Patients could receive a maximum of four laser
photocoagulation throughout the study.
Rescue medication In case of lack of efficacy of the study
treatment and when the investigator deemed it in the best
interests of the patient to receive alternative treatment for
DME in the study eye, the patient was asked to discontinue
the study and was treated outside of the study protocol.
Treatment masking
In order to fulfill masking requirements, the site personnel
consisted of a VA assessor, an evaluating investigator re-
sponsible for all other assessments and treatment decisions,
and a treating investigator. Both the VA assessor and the
evaluating investigator were masked to the treatment
assignment, while treating investigator was unmasked
and performed the treatment according to the assigned ran-
domized treatment arm (A2).
Study objectives
The primary objective was to demonstrate superior efficacy of
ranibizumab 0.5 mg monotherapy (PRN regimen driven by
VA stability) compared with laser photocoagulation for the
treatment of visual impairment due to DME in Chinese pa-
tients, as assessed by the mean average change in BCVA from
Month 1 to Month 12 compared with baseline.
Secondary objectives were to evaluate the following: mean
change in BCVA from baseline at Month 12; mean change in
central subfield thickness (CSFT) from baseline at Month 12;
proportion of patients with BCVA gain of ≥ 10 and ≥ 15 letters
and loss of < 10 and < 15 letters from baseline at Month 12;
proportion of patients with BCVA ≥ 73 letters (approximate
20/40 Snellen chart equivalent) at Month 12; treatment expo-
sure, number of retreatments, and retreatment patterns; and
safety as assessed by ocular and non-ocular adverse events
(AEs) and serious AEs (SAEs) over 12 months.
Other exploratory objectives were to evaluate the effect of
treatment on DR as assessed by proportion of patients with
changes on the ETDRS-diabetic retinopathy severity score
(DRSS) on a 10-point scale (defined in A3), and proportion
of patients progressing from non-proliferative DR (NPDR
[ETDRS-DRSS on 10-point scale < 7 at baseline]) to prolifer-
ative DR (PDR [ETDRS-DRSS on 10-point scale ≥ 7]).
Efficacy and safety assessments
Study assessments were performed at screening (Visit 1), at
baseline (Visit 2), and at monthly visits (every 30 days from
baseline) until Month 12.
End of 
treatment
End of 
study
4 5 7 8 12
MonthsDay −14 
Enrollment/
Screening
Day 1
BSL/R
1 2 3 6 119 10
Arm II–Laser photocoagulation (n=76) 
Arm I–Ranibizumab 0.5 mg and sham laser (n=304) 
Screening
period
Months
Post-treatment 
follow-up period
Treatment period
Laser photocoagulation on Day 1 and sham injection monthly
Ranibizumab 0.5 mg monthly and sham laser on Day 1 
Laser photocoagulation as needed and sham injection PRN  
Ranibizumab 0.5 mg PRN and sham laser as neededFig. 1 Study design. BSL
baseline, E enrollment, PRN pro
re nata, R randomization
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Efficacy assessments
Best-corrected visual acuity BCVAwas assessed in both eyes
at screening, baseline, Months 6 and 12, and in the study eye
at all other visits. The measurements were performed in a
sitting position using ETDRS-like VA testing charts at a test-
ing distance of four meters.
Optical coherence tomography Optical coherence tomogra-
phy was performed in both eyes at screening, Months 6 and
12, and in the study eye at all other visits to monitor disease
activity, specifically CSFT. Images were also analyzed by a
central reading center (CRC) which was masked to treatment.
Fluorescein angiography and color fundus photography FA
was performed in conjunction with color fundus photography
in both eyes at the screening, Month 6, and Month 12 visits to
determine eligibility and monitor disease activity. In addition,
the images were analyzed by a CRC to assess the presence and
the type of DME, the area of leakage, and severity of DR by
using the ETDRS severity scale for the study eye.
Treatment exposure and compliance
Patients were assigned to one of the two treatment arms by
means of the IRT system.
Any deviations from the protocol or the administration of
the active/sham ranibizumab injections as well as active/sham
laser treatments were described on the dosage and administra-
tion record of the electronic Case Report Form.
Safety assessments
Safety was assessed by monitoring and recording all AEs and
SAEs, conducting slit lamp and fundus examinations before
dosing in both eyes at all visits and tonometry to assess intra-
ocular pressure (IOP). IOP measurements (pre-injection and
post-injection) were presented descriptively (absolute values
and change from baseline) by monthly visit for the study eye,
and in the subset of patients with IOP ≥ 30 mmHg.
Statistical analysis
A sample size of 380 patients was required (ranibizumab
304 and laser 76) to ensure that at least 300 patients re-
ceived ranibizumab. Under this sample size, a statistical
power of nearly 100% was expected with a significance
level of 0.025.
For the primary analysis, the following one-sided hypothesis
was tested at a one-sided alpha level of 0.025. The statistical
hypothesis testing was based on a Cochran-Mantel-Haenszel
(CMH) row mean score statistics using a stratified CMH test
with original BCVA values as scores and with stratification
according to DME type (focal, diffuse, honeycomb, and petal-
oid) and baseline BCVA score (≤ 60 letters versus > 60 letters).
A three-way analysis of variance (ANOVA) model with treat-
ment, baseline BCVA category, and DME type as factors were
applied to generate least square (LS) means and two-sided 95%
confidence intervals (CIs).
The primary analysis was performed on the full analysis set
(FAS) with missing values imputed by the mean value last
observation carried forward (MV-LOCF) method. The FAS
comprised all patients in the randomized set (which consisted
of all randomized patients) to whom the study treatment had
been assigned. Following the intent-to-treat principle, patients
were analyzed according to the treatment to which they were
assigned at randomization.
Missing values of other efficacy variables were imputed
by standard LOCF method. For proportion of patients with
a ≥ two-step in ETDRS-DRSS, an additional analysis was
also performed on subgroup of patients with moderately
severe NPDR or worse (ETDRS-DRSS on 10-point scale
≥ 5) at baseline.
Patient disposition was summarized by treatment by using
the randomized set. Descriptive statistics were provided for
patient demographics, baseline diabetes, and ocular character-
istics for all randomized patients by treatment arm.
Descriptive statistics were provided for exposure to the
study treatment by using the safety set. The safety set
consisted of all patients who received at least one application
of study treatment and had at least one post-baseline safety
assessment. Patients were analyzed according to treatment
received. The statement that a patient had no AEs also consti-
tuted a safety assessment. The numbers of ranibizumab, laser,
and sham treatments in the study eye were presented by treat-
ment arm in frequency tables by visit and cumulatively over
12 months. Patients who received both active ranibizumab
and active laser were analyzed under the ranibizumab arm in
the safety analysis.
Results
Patient disposition, baseline demographics, disease,
and ocular characteristics
A total of 384 patients were randomized; 307 to the
ranibizumab 0.5 mg arm and 77 to the laser arm. The majority
(n = 342; 89.1%) of patients completed the 12-month study
period (90.9% in the ranibizumab arm; 81.8% in the laser
arm; Fig. 2). The two most frequent reasons for premature
study discontinuation in the ranibizumab and laser arms were
patients’/guardians’ decision to withdraw consent (2.6% and
10.4%, respectively) and AEs (2.0% and 5.2%, respectively;
Fig. 2). Overall, 10.2% of patients (n = 39) had at least one
protocol deviation (ranibizumab 10.4% and laser 9.1%). The
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most common protocol deviations with an impact on analysis
were related to the eligibility criteria (3.6%) such as a change
in diabetes medication within 3 months prior to enrollment
(1.6%).
Patient baseline demographic, disease, and ocular char-
acteristics were comparable between the treatment arms
(Table 1). All patients were Chinese with a mean (± stan-
dard deviation [SD]) age of 58.7 (8.79) years; 53.6% were
female. The majority of patients (99.0%) had type II diabe-
tes and mean (SD) HbA1c of 7.41 (1.14)%. Focal DME was
the most frequent type of DME present at baseline (34.9%).
The baseline mean (SD) VA was 59.3 (10.32) letters, and
96.9% of patients had an IOP of ≤ 21 mmHg; mean CSFT
(SD) was similar in both treatment arms (ranibizumab
473.4 [166.13] μm; laser 475.0 [161.52] μm), and more
patients had visible cysts in the ranibizumab arm (99%)
(Table 1).
At baseline, a total of 290 (75.5%) patients had moderate
non-proliferative DR or better (NPDR, DRSS < 4), while 94
(24.5%) patients had moderately/severe NPDR or worse
(DRSS scores > 5) based on CRC assessment. DR severity
was balanced between treatment groups.
Prior to the study, 58.3% of patients in the ranibizumab arm
and 67.5% in the laser arm received laser treatment in the
study eye, mostly for DR (62.3% of all patients with prior
laser therapy) and DME (36.8%).
Efficacy and anatomical outcomes
Best-corrected visual acuity The mean (SD) average change in
BCVA from Month 1 to Month 12 compared with baseline
was 6.8 (6.58) letters in the ranibizumab arm and 1.1 (7.73)
letters in the laser arm. The difference in LS means between
the two treatment arms was 5.8 letters (95% CI 4.1, 7.5) and
statistically significant (p < 0.001).
The mean change in BCVA from baseline at Month 12 was
7.8 (8.72) letters in the ranibizumab arm and 2.5 (8.78) letters
in the laser arm (Fig. 3). The difference in LS means between
the two arms was 5.4 letters (95% CI 3.2, 7.6).
A larger proportion of patients in the ranibizumab arm
gained ≥ 10 and ≥ 15 BCVA letters at Month 12 compared
to the laser arm (A4). Similarly, the proportion of patients with
a loss of < 10 and < 15 letters was numerically higher in the
ranibizumab arm compared with the laser arm (A4). The pro-
portion of patients with a BCVA of ≥ 73 letters at Month 12
was numerically greater in the ranibizumab arm compared to
the laser arm (36% versus 21.3%; A4).
A total of 35.8% of patients in the ranibizumab arm and
22.4% of patients in the laser arm reported an improvement by
one or more steps in the ETDRS-DRSS 10-point scale from
baseline to Month 12. At Month 12, 13.0% and 10.4% of
patients had an improvement of a ≥ two-step change in the
ETDRS-DRSS 10-point scale from baseline in the
ranibizumab and laser arms, respectively. Out of the 69 pa-
tients in the ranibizumab arm with moderately severe NPDR
or worse (DRSS ≥ 5) at baseline as determined by the CRC,
37 (53.6%) experienced a ≥ two-step improvement in the
ETDRS-DRSS 10-point scale from baseline, compared to 7
(36.8%) of patients in the laser arm.
The proportion of patients who progressed from NPDR to
PDR from baseline was 2.4% and 3.0% in the ranibizumab
and laser arms, respectively.
Patients randomized 4:1
(N=384)
Ranibizumab 0.5 mg PRN (n=307) 
Total screened=461
14 (18.2%) patients discontinued, n (%): 
• AEs: 4 (5.2)
• Lost to follow-up: 0
• Administrative problems: 0
• Deaths: 0
• Protocol deviation: 0
• Physician’s decision: 2 (2.6)
• Patient/guardian decision: 8 (10.4)
Study completion, n (%)
Month 12: 63 (81.8)
Study completion, n (%)
Month 12: 279 (90.9)
28 (9.1%) patients discontinued, n (%): 
• AEs: 6 (2.0)
• Lost to follow-up: 2 (0.7)
• Administrative problems: 0
• Deaths: 2 (0.7)
• Protocol deviation: 5 (1.6)
• Physician’s decision: 5 (1.6)
• Patient/guardian decision: 8 (2.6)
Not 
randomized=77
Reasons for non-randomization, n (%): 
• Unacceptable past med hist/conc diagnostics: 5 (6.5) 
• Intercurrent medical event: 3 (3.9) 
• Unacceptable laboratory value(s): 27 (35.1) 
• Unacceptable test procedure result(s): 9 (11.7) 
• Did not meet diagnostic/severity criteria: 13 (16.9) 
• Unacceptable use of exclude med/therapy: 2 (2.6) 
• Subject withdrew consent: 7 (9.1) 
• Other: 15 (19.5) 
Laser photocoagulation (n=77)
Fig. 2 Patient disposition
(randomized set). The
randomized set included all
randomized patients to whom a
randomization number was
assigned. Percentages were based
on the total number of patients in
the randomized set in a specific
treatment arm. AE adverse event,
PRN pro re nata
Graefes Arch Clin Exp Ophthalmol
Anatomical outcomes A rapid and clinically relevant de-
crease in CSFTwas observed from baseline during the first
3 months and was maintained up to Month 12 in the
ranibizumab arm. At Month 12, the mean (SD) change in
CSFT was higher in the ranibizumab arm than in the laser
arm (− 146.5 [157.61] μm versus − 85.9 [166.60] μm). The
Table 1 Baseline demographic,
disease, and ocular characteristics
(randomized set)
Characteristics Ranibizumab 0.5 mg PRN (n = 307) Laser (n = 77)
Age, years, mean (SD) 58.6 (8.70) 59.0 (9.19)
Age category (years), n (%)
< 55 80 (26.1) 24 (31.2)
55 to < 65 151 (49.2) 30 (39.0)
65 to < 75 69 (22.5) 21 (27.3)
≤ 75 7 (2.3) 2 (2.6)
Gender, female, n (%) 168 (54.7) 38 (49.4)
Race, Chinese, n (%) 307 (100) 77 (100)
VA (ETDRS letters), mean (SD) 59.6 (10.53) 58.2 (9.43)
CSFT (μm), mean (SD) 473.4 (166.13) 475.0 (161.52)
IOP (mmHg), mean (SD) 15.4 (3.22) 15.0 (3.46)
Diabetes type, n (%)
Type I 3 (1.0) 1 (1.3)
Type IIa 304 (99.0) 76 (98.7)
HbA1c, mean (SD) 7.44 (1.16) 7.30 (1.05)
Time since first diagnosis (years), mean (SD) 1.31 (2.01) 1.10 (1.47)
Time since first diagnosis (years), n (%)
≤ 0.25 103 (33.6) 29 (37.7)
> 0.25–< 1.0 83 (27.0) 21 (27.3)
≥ 1.0 121 (39.4) 27 (35.1)
DME type, n (%)
Focal 111 (36.2) 23 (29.9)
Diffuse 36 (11.7) 6 (7.8)
Honeycomb 67 (21.8) 22 (28.6)
Petaloid 93 (30.3) 26 (33.8)
Any visible cysts, n (%)
No 3 (1.0) 1 (1.3)
Yes 304 (99.0) 75 (97.4)
Cannot grade 0 1 (1.3)
ETDRS DR severity score on original scale, n (%)
10–12 0 0
14–53 268 (87.3) 63 (81.8)
60–85 36 (11.7) 12 (15.6)
98, 99, 0 or missing 3 (1.0) 2 (2.6)
ETDRS DR severity subgroup, n (%)
Moderate NPDR or better (10 to 43) 231 (75.2) 54 (70.1)
Moderately severe NPDR or worse (47 to 85) 73 (23.8) 21 (27.3)
Missing 3 (1.0) 2 (2.6)
The randomized set included all randomized patients towhom a randomization number was assigned. Percentages
were based on the total number of patients in the randomized set in the specific treatment arm. CSFT represents all
data irrespective of types of OCT machines. DME types were assessed by Central Reading Center
CSFT central subfield thickness,DME diabetic macular edema,DR diabetic retinopathy, ETDRS Early Treatment
Diabetic Retinopathy Study, HbA1c glycated hemoglobin, IOP intraocular pressure, NPDR non-proliferative
diabetic retinopathy,OCToptical coherence tomography, PRN pro re nata, SD standard deviation, VAvisual acuity
a Patients with latent autoimmune diabetes in adults are classified as having diabetes mellitus type II
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difference in LS mean change between the two arms
(ranibizumab 0.5-mg minus laser) was 72.5 μm (95% CI
− 111.6, − 33.5 μm) and statistically significant (p < 0.001)
(Fig. 4).
Treatment exposure The mean (SD) number of active
study treatments received in the study eye was 7.9
(2.82) in the ranibizumab arm and 2.1(1.08) in the laser
arm (Table 2).
The mean (SD) number of ranibizumab re-treatments, i.e.,
treatments administered from Month 3 to Month 12 after the
first treatment interruption due to VA stabilization, was 1.6
(0.64) as shown in Table 3 with 32.6% of patients not requir-
ing any further injections. The mean (SD) treatment-free in-
terval for the ranibizumab arm was 3.0 (2.50) months, with a
mean (SD) maximum treatment-free interval of 3.2 (2.52)
months (Table 3). The proportion of patients in the
ranibizumab arm with a maximum treatment-free interval of
≥ 3 months was 39.0%.
Safety outcomes
Overall, 25.4% and 57.3% of patients reported ocular AEs and
non-ocular AEs in the study eye, respectively.
Ocular AEs In total, 27.4% of patients in the ranibizumab arm
and 17.3% of patients in the laser arm reported ocular AEs of
the study eye. The most frequently reported ocular AEs was
IOP increased (ranibizumab 5.2%), followed by vitreous hem-
orrhage (ranibizumab 1.6%; laser 5.3%), conjunctival hemor-
rhage (ranibizumab 3.6%; laser 1.3%), and dry eye
(ranibizumab 3.6%; laser 1.3%) as shown in Table 4. No cases
of endophthalmitis were reported.
The most commonly reported ocular AEs in the study eye
that were suspected to be related to the study drug and/or
injection procedure in the ranibizumab arm were conjunctival
hemorrhage (3.6%) and IOP increased (3.3%) (A5).
Non-ocular AEs Similarly, 57.0% of patients in the
ranibizumab arm and 58.7% of patients in the laser arm expe-
rienced non-ocular AEs. The most frequently reported non-
ocular AEs were hypertension (ranibizumab 6.2%; laser
13.3%) and nasopharyngitis (ranibizumab 6.5%; laser 9.3%)
followed by upper respiratory tract infection (ranibizumab
8.5%; laser 2.7%) and cough (ranibizumab 5.9%; laser
2.7%; Table 4). None of the non-ocular AEs were suspected
to be related to the study drug.
Overall, a similar proportion of patients experienced SAEs
in both treatment arms (ranibizumab 18.9% and laser 21.3%).
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Ocular SAEs Cataract was reported in 0.3% of patients in the
ranibizumab arm and vitreous hemorrhage in 1.3% of patients
in the laser arm (Table 5).
Non-ocular SAEs The non-ocular SAEs were reported in
16.3% of patients in the ranibizumab arm and 14.7% of pa-
tients in the laser arm. Two deaths were reported in the
ranibizumab arm (one with sudden death and one due to pneu-
monia) which were considered not related to the study treat-
ment and/or injection procedure (Table 5).
Discussion
REFINE is the first study conducted in the mainland Chinese
population to assess the efficacy and safety data on
ranibizumab 0.5 mg compared with laser photocoagulation,
the current standard of care, in patients with visual impairment
due to DME. In this study, ranibizumab 0.5 mg dosed PRN
(driven by VA stability) demonstrated superior efficacy over
laser photocoagulation in improving BCVA from baseline to
Month 1 to Month 12 compared with baseline. The difference
Table 2 Treatment exposure and
frequency of treatments (safety
set)
Number of treatment Ranibizumab 0.5 mg PRN (n = 307) Laser (n = 75)
Total 2426 156
Mean (SD) 7.9 (2.82) 2.1 (1.08)
Median 8.0 2.0
Frequency of study treatments, n (%)
1 5 (1.6) 29 (38.7)
2 2 (0.7) 22 (29.3)
3 23 (7.5) 13 (17.3)
4 14 (4.6) 11 (14.7)
5 23 (7.5) 0
6 26 (8.5) 0
7 34 (11.1) 0
8 33 (10.7) 0
9 44 (14.3) 0
10 40 (13.0) 0
11 33 (10.7) 0
12 30 (9.8) 0
The safety set consisted of all patients who received at least one application of study treatment and had at least one
post-baseline safety assessment. Percentages are based on the number of patients in the safety set in the specific
treatment arm
PRN pro re nata, SD standard deviation
Table 3 Number of ranibizumab
re-treatments received from
Month 3 (safety set)
Exposure Ranibizumab 0.5 mg PRN (n = 307)
Re-treatment with ranibizumab from Month 3
Total 319
Mean (SD) 1.6 (0.64)
Treatment free interval (months) for the ranibizumab arm
Total 254
Mean (SD) 3.0 (2.50)
Duration of treatment free interval for ranibizumab from Month 3a
Maximum treatment free interval (months), mean (SD) 3.2 (2.52)
A ranibizumab re-treatment is defined as an administration of ranibizumab injection at a scheduled visit following
at least one non-missed visit where ranibizumab was not administered in the study eye due to visual acuity
stabilization. Only applicable for patients in ranibizumab arm
aMissing visits were included in the calculation of the duration of ranibizumab treatment free intervals. The end of
study visit was not included in any calculation. First visit of a ranibizumab treatment free interval had to be an
attended visit, following a ranibizumab injection visit
PRN pro re nata, SD standard deviation
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Table 4 Ocular (study eye) and
non-ocular adverse events re-
gardless of study drug relation-
ship (≥ 3% in any arm) by pre-
ferred term (safety set)
Preferred term, n (%) Ranibizumab 0.5 mg PRN (n = 307) Laser (n = 75)
Ocular AE (total) 84 (27.4) 13 (17.3)
IOP increased 16 (5.2) 0
Conjunctival hemorrhage 11 (3.6) 1 (1.3)
Dry eye 11 (3.6) 1 (1.3)
Vitreous hemorrhage 5 (1.6) 4 (5.3)
Non-ocular AEs (total) 175 (57.0) 44 (58.7)
Upper respiratory tract infection 26 (8.5) 2 (2.7)
Nasopharyngitis 20 (6.5) 7 (9.3)
Hypertension 19 (6.2) 10 (13.3)
Cough 18 (5.9) 2 (2.7)
Urinary tract infection 15 (4.9) 3 (4.0)
Diabetic nephropathy 14 (4.6) 2 (2.7)
Diabetic neuropathy 12 (3.9) 2 (2.7)
Anemia 10 (3.3) 0
Hyperlipidemia 9 (2.9) 3 (4.0)
Alanine aminotransferase increased 3 (1.0) 4 (5.3)
The safety set included all patients who received at least one application of study treatment and has at least one
post-baseline safety assessment. A patient with multiple incidences of an AE under one treatment was counted
only once in the AE category. AEs with start date on or after the date of first administration of study treatment in
the study eye were counted
AE adverse event, IOP intraocular pressure, PRN pro re nata
Table 5 Ocular (study eye; all
patients) and non-ocular (≥ two
patients in any arm) serious ad-
verse events regardless of study
drug relationship by preferred
term (safety set)
Preferred term, n (%) Ranibizumab 0.5 mg PRN (n = 307) Laser (n = 75)
Ocular SAEs (total) 1 (0.3) 1 (1.3)
Cataract 1 (0.3) 0
Vitreous hemorrhage 0 (0.0) 1 (1.3)
Non-ocular SAEs (total) 49 (16.0) 11 (14.7)
Diabetes mellitus inadequate control 4 (1.3) 2 (2.7)
Diabetic neuropathy 3 (1.0) 1 (1.3)
Angina unstable 2 (0.7) 0
COPD 2 (0.7) 0
Diabetic vascular disorder 2 (0.7) 0
Hypertension 2 (0.7) 1 (1.3)
Hypoglycemia 2 (0.7) 0
Lung infection 2 (0.7) 0
Pneumonia 2 (0.7) 0
Diabetic foot 1 (0.3) 2 (2.7)
Deatha 2 (0.7) 0
Sudden death 1 (0.3) 0
Pneumonia 1 (0.3) 0
The safety set included all patients who received at least one application of study treatment and has at least one
post-baseline safety assessment
A patient with multiple occurrences of an SAE under one treatment was counted only once in the SAE category
SAEs with start date on or after the date of first administration of study treatment in the study eye were counted
COPD chronic obstructive pulmonary disease, PRN pro re nata, SAE serious adverse event
a Not related to the study drug
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in LS means between both treatment arms was statistically
significant (p < 0.001) and clinically meaningful. This im-
provement in BCVAwas rapid during the first 3 months and
was maintained throughout Month 12 in patients treated with
ranibizumab 0.5 mg, while there was no meaningful improve-
ment in BCVA in patients treated with laser. Anatomical out-
comes further supported these functional improvements
where the reduction in CSFT was higher in patients treated
with ranibizumab than those treated with laser. More patients
gained ≥ 10 and ≥ 15 letters in the ranibizumab arm than in the
laser arm. With regard to the DR severity as assessed by the
CRC, results demonstrated that more patients improved in the
ranibizumab arm compared with the laser arm. This effect was
more prominent in the group of patients with moderately se-
vere NPDR or worse at baseline, where more than half of
patients in the ranibizumab arm improved by 2 or more steps
on the ETDRS-DRSS 10-point scale.
The findings of REFINE are consistent with the previ-
ous pivotal studies such as RESOLVE16 and RESTORE17.
The mean change in BCVA letter score from baseline at
Month 12 among REFINE, RESOLVE15, and RESTORE16
studies was similar in the ranibizumab arm (7.8, 10.3, 6.8
letters, respectively) and the laser arm (2.5, − 1.4, 0.9 let-
ters, respectively). A comparable proportion of patients
gained ≥ 10 letters as well as ≥ 15 letters in the
ranibizumab arm from baseline at Month 12 in REFINE,
RESOLVE16, and RESTORE17 (gain of ≥ 10 letters 40.6%,
60.8%, 37.4%, respectively; and gain of ≥ 15 letters
18.5%, 32.4%, 22.6%, respectively). At Month 12, the
mean number of ranibizumab injections was also similar
among the REFINE, RESOLVE16, and RESTORE17 stud-
ies (7.9, 10.2, and 7.0, respectively).
Ranibizumab 0.5 mg was well-tolerated in the Chinese
patients with visual impairment due to DME. Overall, the
ocular and non-ocular AEs reported in the study eye were
comparable between treatment arms, and no new AEs re-
lated to ranibizumab safety concerns were identified. The
safety signals were consistent with the well-established
safety profile of ranibizumab in previous DME studies
[15, 16, 21].
Due to the nature of this study, there was no ethnical diver-
sity and the study population was limited to mainland China.
The REFINE study is the first to represent a large Chinese
patient population with visual impairment due to DME. This
study was adequately powered and therefore yielded highly
significant results. The study was well-controlled and the cen-
tral reading center ensured consistent interpretation of the an-
atomical outcomes.
In conclusion, given the clinical benefit achieved in the
ranibizumab arm and the well-established safety profile of
ranibizumab, the REFINE study results support the use of
ranibizumab 0.5 mg PRN in Chinese patients with visual im-
pairment due to DME.
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